Supplementary Figure S1. Proposed mechanism of neutrophilic pustule formation during ustekinumab therapy (JDCR-D-26-01169R2)

Published: 17 November 2026| Version 1 | DOI: 10.17632/yx65kgvxfm.1
Contributor:

Description

Supplementary material for: "Ustekinumab-associated subcorneal pustular eruption with positive rechallenge in Crohn's disease" (JAAD Case Reports, Ms. Ref. No. JDCR-D-26-01169R2). Figure legend: Supplementary Figure S1. Proposed mechanism of neutrophilic pustule formation during ustekinumab therapy: IL-23 blockade may disturb the IL-23/IL-36 balance, permitting IL-36-driven neutrophil recruitment and pustulation, a pathway shared by pustular psoriasis and subcorneal pustular dermatosis (SPD). Compensatory immune drift (TNF-α, IL-1β, IL-17, IFN-γ; putative pDC-derived IFN-α) activates keratinocyte IL-36α/β/γ signaling through IL-36R (MyD88/IRAK–NF-κB/MAPK, JAK-independent), inducing CXCL1 and CXCL8/IL-8–mediated neutrophil chemotaxis. Neutrophil elastase and cathepsin G proteolytically activate pro-IL-36, creating a positive feedback loop that culminates in subcorneal pustule formation. The JAK1-selective inhibitor upadacitinib attenuates upstream cytokine signaling (IFN-γ, IL-6, IL-2) but does not directly block IL-36R.

Files

Categories

Clinical Medicine

Licence